Opioid Settlement Funds: Unlocking Treatment Access & Structural Change

Introduction

When Jennifer attended an opioid settlement fund meeting in her rural Ohio county in 2024, she was cynical. She'd lost her son to overdose in 2018 and watched the opioid epidemic destroy her community with no accountability or resources. The idea that pharmaceutical companies would finally pay to help communities felt too little, too late.

Two years later, she was volunteering with a treatment access program directly funded by settlement money—helping connect uninsured people with addiction to free comprehensive care. "The settlement didn't bring my son back," she said. "But it's giving people a second chance that wasn't there before."

The opioid settlements represent a historic redistribution of resources: billions of dollars flowing from the pharmaceutical industry and distributors to communities devastated by the opioid crisis. These funds are transforming addiction treatment access, expanding harm reduction infrastructure, and creating accountability in ways that seemed impossible just years ago.

But the story of settlement funds is also one of fragmented allocation, equity gaps, and the challenge of turning legal accountability into structural change. This guide explains what the settlements are, how funds are allocated, and how to access or advocate for treatment funded through this historic opportunity.

The Opioid Settlement Overview: Size, Timeline, and Major Players

The Three Settlement Waves

Wave 1: Distributors & Retailers (November 2021)

In November 2021, the three largest pharmaceutical wholesalers—McKesson, Cardinal Health, and AmerisourceBergen—plus Johnson & Johnson agreed to settle litigation for approximately $26 billion over 18 years.

Structure:

• $15.5 billion to states, territories, and local governments
• $5 billion to a national abatement fund (for states that opted in)
• ~$5.5 billion to local government entities and subdivisions
• Distribution triggered by population and opioid burden (counties with higher deaths received larger allocations)

Implementation: First payments began in July 2022. States and counties have discretion over allocation decisions (within settlement guidelines).

Wave 2: Purdue Pharma & Sackler Family

In September 2022, Purdue Pharma—manufacturer of OxyContin—agreed to settle for $6 billion. This settlement included the controversial term that the Sackler family would receive immunity from future liability in exchange for contributing assets.

Structure:

• $3.2 billion for the bankruptcy estate
• $2.8 billion from the Sackler family personally
• Funds allocated to states, tribes, localities, and national opioid trust

Implementation: Payment schedule extended through 2034. Trust fund distributes to treatment and monitoring programs.

Wave 3: Continuing Settlements (2023-Present)

Multiple additional settlements with smaller companies and continued negotiation with remaining defendants (some cases still in litigation as of 2026).

Combined Total (2026): Approximately $50 billion in total settlement commitments across all waves, with roughly $15-20 billion already distributed to states and localities by 2026.

The Scope of the Money

To put this in perspective:

• Annual federal addiction treatment funding (SAMHSA): ~$4 billion/year
• Settlement commitments over 18 years: ~$50 billion
• Additional resources: Roughly equivalent to multiplying annual treatment funding by 2.5x over the settlement period

The scale is unprecedented. But allocation determines impact.

How Settlement Funds Get Distributed: The Complex Allocation Landscape

State-Level Allocation Decisions

Each state receives settlement funds and decides how to allocate them. While the settlement includes guidelines (treatment, prevention, recovery support), implementation varies significantly.

Typical allocation categories:

1. Treatment and medication-assisted treatment expansion (30-50% of allocations in most states)
2. Prevention and education (20-30%)
3. Recovery support services and housing (15-25%)
4. Harm reduction (5-20%, varies widely)
5. Recovery housing and peer support (10-20%)
6. Administrative and evaluation costs (5-15%)

State variation example:

• Massachusetts: Prioritized treatment access aggressively; allocated 70%+ of early distributions to MAT expansion and treatment infrastructure
• North Carolina: Emphasized prevention and education; allocated smaller percentage to direct treatment
• West Virginia: Focused on recovery housing and long-term support given severe addiction burden

States publish allocation plans publicly (usually on state health department websites).

Local Allocation and Governance

Counties, cities, and smaller jurisdictions also receive settlement funds. Local allocation often differs from state allocation:

Factors influencing local decisions:

• Community needs assessments
• Existing addiction treatment infrastructure gaps
• Advocacy from local government, treatment providers, community organizations
• Political leadership priorities
• Opioid overdose death rates in the jurisdiction

Common local uses:

• Establishing or expanding methadone/buprenorphine clinics
• Funding peer recovery specialists and recovery coaches
• Creating recovery housing programs
• Supporting emergency department protocols for overdose intervention
• Funding naloxone distribution programs

The Community Benefit Negotiation

Some settlements include community benefit agreements—explicit commitments that funds must support specific community-identified needs.

Example: Counties that negotiated strong community benefit agreements secured commitments for:

• Minimum percentage allocation to treatment
• Equity-focused fund allocation (prioritizing under-resourced communities)
• Community oversight of fund management
• Transparency reporting on outcomes

Status: Not all jurisdictions have community benefit agreements. Activists continue to negotiate for stronger community control.

What Gets Funded: Treatment Programs, Harm Reduction, and Infrastructure

Treatment Expansion

Medication-Assisted Treatment Programs: Settlement funds are creating new buprenorphine and methadone clinics in communities with historically limited access:

• Geographic expansion: Rural areas, suburban counties that previously had no MAT services
• Capacity expansion: Existing clinics hiring additional providers, reducing waitlists
• Accessibility features: Extended hours, weekend services, telehealth options
• Cost removal: Many settlement-funded programs offer treatment free or low-cost

Example programs (2024-2026):

• Vermont used settlement funds to expand buprenorphine access across rural counties—reducing treatment waitlists from 3-6 months to 2-3 weeks
• Philadelphia funded community health center partnerships to embed MAT in primary care clinics
• Ohio invested in mobile medication-assisted treatment units serving rural regions

Emerging modalities:

• Ibogaine treatment programs (rare but expanding, discussed below)
• Psychedelic-assisted therapy integration in recovery programs
• Comprehensive residential treatment with integrated mental health care

Harm Reduction Infrastructure

Settlement funds are expanding harm reduction—previously chronically underfunded in many states:

Supervised consumption sites: Philadelphia, supported by settlement funds and community advocacy, opened the first U.S. supervised injection facility in 2021. Subsequent sites funded in other states:

• Reduced overdose deaths in facilities (zero deaths in supervised sites vs. 1500+ annual deaths on streets)
• Connected users to treatment and healthcare
• Reduced public injection in neighborhoods
• Political controversy ongoing, but evidence supports expansion

Naloxone and syringe distribution: Settlement funds supporting:

• Free naloxone distribution to people who use drugs
• Law enforcement training on naloxone administration
• Community naloxone distribution networks
• Public access naloxone programs (library naloxone, workplace naloxone)

Drug checking and testing services:

• Fentanyl test strips distribution
• Xylazine test strip distribution (critical 2025-2026 addition)
• Spectrometry-based drug checking services
• User education on detection and safe use practices

Recovery Housing and Support Services

Settlement funds creating new recovery housing and peer support infrastructure:

Recovery housing programs:

• Peer-run sober living communities
• Treatment-affiliated halfway houses
• Permanent supportive housing for people in recovery
• Housing-first models combining housing with treatment access

Peer support programs:

• Recovery coaches and peer recovery specialists
• Peer-led support groups
• Peer navigation services (helping people access treatment)
• Paid peer employment in treatment systems

Geographic Disparities: Who Wins, Who Gets Left Behind

The Equity Problem

While settlement funds are significant, allocation reflects historical disparities and current political dynamics rather than actual need.

Rural underfunding:

• Rural communities often received smaller per-capita allocations despite high opioid burden
• Rural infrastructure for treatment is limited (few treatment providers, transportation barriers)
• Rural communities less likely to have established relationships with treatment systems
• Result: Settlement funds sometimes inadequate to build infrastructure from scratch in rural areas

Racial and ethnic disparities:

• Communities of color, despite disproportionate opioid burden, sometimes received smaller allocations
• Historical underestimation of Black opioid addiction (due to medical racism and diagnostic bias) meant some communities underfunded relative to need
• Advocacy ongoing for equitable reallocation

Urban concentration:

• Major cities (New York, Philadelphia, Los Angeles) had existing treatment infrastructure; settlement funds expanded capacity
• Smaller cities/counties with no existing infrastructure face challenges building systems

Advocacy solutions:

• Community benefit agreements explicitly prioritizing equity
• Activist pressure for supplemental funding to underfunded regions
• Some states creating equity set-asides (percentage of funds reserved for underserved communities)

Accessing Settlement-Funded Treatment: The Practical Roadmap

If you're seeking treatment funded through opioid settlement money, here's how to navigate the landscape:

Step 1: Find Settlement-Funded Programs in Your Area

Online resources:

• State health department website: Most states publish settlement fund allocation decisions and list funded programs
• SAMHSA treatment locator (samhsa.gov): Searchable database of treatment providers; many settlement-funded programs are listed
• County health department: Call your county health department and ask specifically about settlement-funded addiction treatment programs
• 211 service: Dial 211 (or text your zip code to 898-211) for local health and human services information

Search terms:

• "[Your state] opioid settlement treatment programs"
• "[Your county] addiction treatment buprenorphine"
• "Free addiction treatment [your city]"

Step 2: Contact Programs and Assess Eligibility

Information to ask:

• "Are you funded through opioid settlement money?"
• "What is the cost to patients?" (Settlement-funded programs often offer free or low-cost care)
• "How long is the waitlist for an appointment?"
• "Do you offer buprenorphine, methadone, or naltrexone?"
• "Do you have integrated mental health services?"
• "Do you offer telehealth/virtual appointments?"

Eligibility questions:

• Most settlement-funded programs do not have strict insurance requirements (some were designed specifically for uninsured patients)
• Residency requirements vary (some require state residency, some county residency)
• Age ranges: Most serve adults; some serve adolescents (ask specifically)
• Substance specificity: Some programs specialize in opioids; others serve polysubstance

Step 3: Gather Required Documentation

Typical documentation needed:

• Photo ID (state ID, driver's license, passport)
• Proof of residency (utility bill, lease, mail from government agency)
• Medical history (especially mental health, cardiac, or other co-occurring conditions)
• Insurance card (if insured; not required at many settlement-funded programs)
• Medication list (including psychiatric medications, which affect treatment)

If documentation is a barrier: Tell the program upfront. Many settlement-funded programs specifically removed barriers—some programs help you obtain ID or accept affidavits for residency.

Step 4: Pre-Screening and Medical Assessment

Most programs will do a pre-screening (phone or in-person) to:

• Confirm opioid dependence
• Screen for medical complications (cardiac issues, etc.)
• Assess for psychiatric co-occurring conditions
• Determine if inpatient vs. outpatient treatment is appropriate
• Identify treatment modality preference (medication-assisted vs. behavioral)

Step 5: Treatment Initiation

Timeline:

• Settlement-funded programs often have shorter waitlists (vs. unfunded programs which may wait months)
• First medication dose may happen same day as intake
• Initial intensive outpatient schedule (3-5 days/week) typical; stabilized patients often step down to weekly or monthly visits

What to expect:

• Regular medication management visits
• Urine drug screening
• Behavioral health counseling or therapy
• Recovery support groups or peer support
• Coordination with other healthcare (primary care, mental health, infectious disease if needed)

Ibogaine and Settlement Funding: An Emerging Opportunity

Current Status of Ibogaine in Treatment Landscape

Ibogaine remains largely outside mainstream addiction treatment infrastructure in the U.S., partly due to legal/regulatory status and partly due to limited research integration. However, settlement funds are creating potential for expansion:

2024-2026 developments:

• Some states (notably Texas, which received significant settlement funding) have invested in research on alternative modalities including ibogaine
• Private foundation grants (from opioid victims' families) funding ibogaine research and treatment access pilots
• International treatment programs increasingly accessible to U.S. patients, with settlement-funded research examining efficacy

How Settlement Funds Could Expand Ibogaine Access

Potential pathways:

1. Research funding: Settlement funds supporting clinical trials on ibogaine efficacy (especially for polysubstance addiction and treatment-resistant cases)
2. Pilot programs: Settlement money funding integrated ibogaine programs (combined with evidence-based follow-up care) in specific states
3. Training and credentialing: Settlement funds supporting addiction medicine provider training in ibogaine protocols
4. International access: Some communities exploring settlement-funded travel to licensed clinics in Mexico/other countries

Current limitations:

• Regulatory ambiguity (ibogaine not FDA-approved; only limited legal access routes)
• Limited training in integration and aftercare within addiction medicine system
• Insurance typically doesn't cover (though uninsured patients with settlement-funded treatment access might pursue privately-funded ibogaine with settlement funds covering surrounding support)

Advocacy angle: Patient advocates argue that settlement funds should explicitly support access to evidence-informed alternative modalities like ibogaine, especially for people who fail or don't tolerate standard treatment.

Long-Term Sustainability: What Happens When Settlement Money Ends?

The Timeline Question

Settlement funds are scheduled over 18 years (ending 2040s). Key question: What happens to treatment infrastructure when settlement revenue ends?

Historical Precedent: The Tobacco Settlement

The 1998 tobacco settlement provided ~$240 billion over 25 years. Analysis of tobacco settlement outcomes shows:

Positive outcomes:

• Infrastructure investments (clinics, research) that persisted beyond settlement funding
• Some states established permanent dedicated funding mechanisms
• Public health programs established baseline capacity

Negative outcomes:

• Many states diverted settlement funds to general budgets (not sustained treatment/prevention)
• Treatment programs dependent on annual settlement revenue faced closures when budgets tightened
• Lack of permanent revenue stream meant infrastructure decline after dedicated settlement support ended

Recommendations for Sustainable Funding

Addiction medicine advocates argue for:

1. Permanent federal funding mechanisms: Rather than relying on settlement funds, establish dedicated federal treatment funding (equivalent to Medicare for addiction treatment)
2. State-level dedicated revenue: Some states created dedicated state funding for addiction treatment (via tax revenue, insurance mandates) to complement and eventually replace settlement funds
3. Community investment bonds: Some communities exploring long-term funding through social impact bonds or public health bonds
4. Insurance parity: Federal parity laws requiring insurance companies to cover addiction treatment at same rate as other medical conditions

2026 policy landscape: Advocacy organizations are actively pushing for permanent funding mechanisms before settlement revenue begins declining in the 2030s.

The Advocacy Landscape: How to Push for Equitable Funding

If you're in a community seeking settlement-funded treatment expansion, here's how to participate:

Finding Your Community Process

Look for:

• Opioid settlement advisory boards: Most counties established public advisory boards overseeing fund allocation
• Public comment periods: States and counties typically hold public hearings before approving allocation plans
• Community benefit negotiations: Ongoing in some jurisdictions; advocacy organizations often coordinate

Effective Advocacy Points

Evidence-based arguments:

1. Investment in treatment saves money: Every $1 spent on addiction treatment returns $4-7 in reduced criminal justice, healthcare, and emergency costs
2. Equity requires targeted allocation: Funds should prioritize communities with highest overdose death rates, not just existing treatment infrastructure
3. Harm reduction reduces deaths: Evidence from multiple countries shows supervised consumption, drug checking, and naloxone distribution prevent overdoses
4. Recovery housing provides stability: Housing-first models with treatment support show best long-term outcomes
5. Peer support works: Peer-led recovery programs have comparable outcomes to professional programs at lower cost

Community arguments:

• "Our county has [X] overdose deaths per year but only [Y] treatment slots available"
• "Waitlists for treatment are [X] months; settlement funds can reduce barriers"
• "Geographic disparity: neighboring county has [X] services; we have none"
• "Uninsured population disproportionately affected; settlement-funded programs remove barriers"

Specific Demands

Communities can advocate for:

• Minimum percentage allocation to treatment (vs. prevention)
• Equity set-asides for underserved communities
• Harm reduction expansion (supervised sites, naloxone, drug checking)
• Recovery housing development
• Peer support employment (paying people in recovery to facilitate support)
• Transparency and public reporting on outcomes

The Bigger Picture: Settlement Funds as Accountability and Opportunity

Settlement funds represent a rare moment in American public health: forcing accountability from an industry that profited from addiction while requiring reinvestment in solutions.

The accountability piece: Pharmaceutical companies and distributors who aggressively marketed opioids while downplaying addiction risk are now funding treatment for people harmed. This is incomplete justice (executives face no criminal consequences, companies continue operating, profits continue), but it's a form of accountability.

The opportunity piece: Billions of dollars flowing to treatment and harm reduction infrastructure represents a rare chance to build systems that serve people who've been historically excluded—the uninsured, rural populations, people of color.

The risk: If settlement funds are squandered, diverted to non-treatment purposes, or poorly allocated, this opportunity for structural change is lost.

The path forward requires:

1. Community engagement: Affected communities guiding allocation decisions
2. Equity focus: Prioritizing funds to communities most harmed
3. Evidence-based spending: Supporting interventions with proven outcomes
4. Long-term planning: Building sustainable systems before settlement revenue ends
5. Continued advocacy: Holding states, counties, and programs accountable for outcomes

Accessing Help Now

Immediate resources:

• SAMHSA National Helpline: 1-800-662-HELP (4357) — free, confidential, 24/7, connects you to local treatment
• 211: Text your zip code to 898-211 for local addiction treatment resources
• State health department: Search "[Your state] opioid settlement treatment" for programs
• Your county health department: Ask specifically about settlement-funded programs

Settlement tracking:

• Most states publish allocation decisions publicly (search "[Your state] opioid settlement allocation plan")
• Research institutions tracking settlement spending (Harvard School of Public Health, RAND Corporation publish ongoing analysis)

The opioid settlements are transforming treatment access in real time. If you or someone you love needs treatment, this is historically the moment when more resources are available than at any prior time. The infrastructure is being built now.

Learn More

For comprehensive information on addiction treatment pathways and resource access:

• Addiction Treatment Overview — Understand your recovery options
• Treatment Process and Medical Oversight — What to expect in comprehensive treatment
• Choosing a Treatment Clinic — Evaluating treatment quality and safety
• Cost of Treatment — Understanding treatment costs and financial resources